Biomerica, Inc. BMRA 深 滬
已收盤 09-05 16:00:00 美东时间
2.75
-0.070
-2.48%
華盛通- 最 高2.79
- 今 開2.75
- 成交量 12.97万股
- 最 低 2.53
- 昨 收 2.82
- 總市值 700.10万
- 52周最高 10.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.08
- 委 比 89.75%
- 總股本 254.58万
- 歷史最高 187.12
- 量 比 0.09
- 振 幅 9.22%
- 歷史最低 1.932
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomerica shares are trading higher after the UAE Ministry of Health and Prevention approved the company's Fortel Kidney Test for home use.
Biomerica shares are trading higher after the UAE Ministry of Health and Preven...
09-03 20:20
Biomerica Reports Fiscal 2025 Year End Results
Biomerica reported net sales of $5.3 million in Fiscal 2025, slightly lower than FY 2024 due to global tariff uncertainties and product mix shifts. Operating expenses decreased by $1.3 million, achieving a 19% improvement in operating loss to $5.1 million. Strategic growth areas include advancing inFoods® IBS reimbursement pathways, expanding EZ Detect™ and H. pylori sales, and pursuing MENA market opportunities. Key milestones include PLA code i...
08-29 21:12
Reported Earlier: Biomerica's 10-Minute H. Pylori Home Test Approved In UAE
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1
08-14 22:19
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
Biomerica's Fortel® Ulcer Test, a 10-minute home test detecting Helicobacter pylori (H. pylori), has been approved for use in the UAE. H. pylori, linked to 80% of gastric cancer cases, is classified as a Class 1 carcinogen by the WHO. Gastric cancer is the fifth most common cancer globally. The test, detecting antibodies to H. pylori, which causes peptic ulcers and dyspepsia, aims to improve early detection and treatment. UAE's 41% population is ...
08-14 12:19
Reported Earlier: Biomerica Has Been Granted Canadian Patent Number 3145879 Titled "COMPOSITIONS, DEVICES, AND METHODS OF IBS SENSITIVITY TESTING".
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3145879/summary.html
07-11 09:03
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
Biomerica, Inc. announced that the American Medical Association has issued a new CPT® code for its inFoods® IBS test, enabling insurance reimbursement and expanded patient access. The test identifies personalized food triggers to alleviate IBS symptoms like bloating, pain, diarrhea, and constipation, offering a non-drug solution. Biomerica’s CEO and CCO highlighted the PLA code milestone as a step toward broader adoption and improved patient outc...
07-02 12:08
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica Inc. appoints Scott Madel as Chief Commercial Officer, leveraging his 20+ years of experience in healthcare diagnostics and organizational growth. Madel successfully led turnarounds and scaled revenues at Boston Heart Diagnostics and Genova Diagnostics. He will drive commercialization of inFoods® IBS, a diagnostic-guided therapy for identifying food triggers in gastrointestinal conditions. Published clinical trials demonstrate its effic...
06-26 12:19
Biomerica Appoints Eric B. Chin to Board
Biomerica ( ($BMRA) ) has issued an update. On June 4, 2025, Cathy Coste resign...
06-06 21:47
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Biomerica appoints Eric B. Chin to its Board of Directors, effective June 4, 2025. Mr. Chin, with over 20 years of financial experience in healthcare, will serve as Chair of the Audit Committee and member of other key committees. Currently Akido Labs' CFO, he helped raise $60 million in a recent financing. His加入加强了Biomerica的公司治理和财务监督，支持其商业化扩展。Biomerica is a global biomedical companydeveloping advanced diagnostic and therapeutic products,including...
06-06 13:30
